Palliative Radiation for Advanced Cervical Cancer

Launched by TATA MEMORIAL HOSPITAL · Jun 22, 2019

Keywords

ClinConnect Summary

This clinical trial is studying two different schedules of radiation therapy for women with advanced cervical cancer, specifically those whose cancer has progressed to a stage where it is no longer treatable with a full course of radiation or chemotherapy. The trial compares a faster treatment option that lasts one week to a longer treatment option that takes 6 to 8 weeks. The goal is to see which schedule is more effective in easing pain and improving quality of life for patients.

To participate in this trial, women aged 27 to 93 with locally advanced cervical cancer (Stage IIIB to IVA) may be eligible if they have severe pain, expected survival of less than 12 months, and certain health conditions that make aggressive treatments unsuitable. Important considerations include having significant cancer growth affecting nearby organs or having kidney function issues. Participants will receive targeted radiation to help manage their symptoms and will be closely monitored throughout the treatment process. If you or a loved one fits these criteria, this trial could provide a valuable option for improving comfort during a challenging time.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• 1. Locally advanced cervical cancer (Stage IIIB-IVA) deemed unsuitable for full course radical pelvic radiotherapy or chemoradiation due to the following reasons:
• • Very large volume hard fixed disease infiltrating pelvic wall muscles and ligaments on clinical examination also classified clinically as "frozen pelvis" wherein curative intent treatment is not envisaged or feasible.
• • Fistulous communication between tumour growth and rectum and bladder \>2x2 cm in size (as judged by cystoscopy for bladder infiltration or clinical or proctosigmoidoscopy examination for rectal/sigmoid infiltration) wherein radical intent treatment is not intended or feasible and patient is not a candidate for pelvic exenteration.
• • Deranged renal parameters as measured by Serum Creatinine \>3 mg/dl wherein diversion nephrostomy is not planned by the multidisciplinary team due to anticipated poor clinical outcomes.Furthermore concurrence for palliative intent radiotherapy should be corroborated by 2 staff radiation oncologists.
• • 2. Moderate to Severe Pain on Numerical Rating Score (Score 4 or higher).
• • 3. Anticipated survival \< 12 months.
• • 4. Patients with stage IVB with local disease extent as described in section 1 but systemic chemotherapy is not possible either due to deranged renal function or anticipated poor tolerance.
• Exclusion Criteria:
• • 1. Patients with distant metastasis needing upfront systemic therapy.
• • 2. Presence of retroviral disease
• • 3. Non-compliant for follow up.
• • 4. Expected survival \<3 months.